报价延迟最少15分钟:2025/09/18 14:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.4005 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.62/--
|
|
企业价值
475.50M
|
| 资产负债 |
|
每股账面净值
4.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
490.74M
|
|
每股收益
16.95
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/18 14:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment. |
